| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | ||
| 3 | Generic | axatilimab | |
| 4 | Indication | GvHD | |
| 5 | MOA | CSF-1R mab | |
| 6 | Economics | SNDX? | |
| 7 | Clinical Trials | ||
| 8 | Phase II "AGAVE-201" 3L+ GvHD |
| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | ||
| 3 | Generic | axatilimab | |
| 4 | Indication | GvHD | |
| 5 | MOA | CSF-1R mab | |
| 6 | Economics | SNDX? | |
| 7 | Clinical Trials | ||
| 8 | Phase II "AGAVE-201" 3L+ GvHD |
Martin Shkreli